<DOC>
	<DOCNO>NCT00294476</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy IVIG treatment metastatic cancer prostate , colon melanoma .</brief_summary>
	<brief_title>IVIG Treatment Metastatic Cancers Prostate , Colon Melanoma</brief_title>
	<detailed_description>This study one arm , open label , multi-center , phase II study . Its aim evaluate safety efficacy IVIG administer treatment metastasis solid tumor . IVIG proven affect growth tumor metastasis animal ’ model . Study population include male female , 18 old , diagnose primary tumor ( colon , melanoma prostate ) measurable metastasis ( accord RECIST criterion ) soft tissue and/ tumor marker prostate cancer , good alternate treatment . The patient receive IVIG calculate 1g/kg/bodyweight per cycle ( define every 21 day ) progression disease note . All patient follow period 6 month patient ’ withdrawal .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Urologic Neoplasms</mesh_term>
	<criteria>Patients older 18 year age . Histological confirm diagnosis prostate adenocarcinoma , melanoma colon cancer At least one measurable site disease evidence CT MRI , RECIST criterion soft tissue OR lymph node OR tumor marker appropriate Rising PSA 3 consecutive week take least one week apart value least 5 ng/mL Testosterone le 50 ng/dL prostate patient Prostate cancer patient receive radiation therapy le 30 % pelvic/total bone mass acute radiation toxicity resolve ECOG Performance status 0 2 WBC &gt; 1,500 cells/mm3 , hemoglobin &gt; 9 g/dL , platelet &gt; 100,000 cells/mm3 &lt; 500,000 cells/mm3 Adequate renal function : serum creatinine &lt; 2.0 mg/dL , CCT &gt; = 50 ml/min Life expectancy least 3 month Willing participate 6 month followup Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . Post menopausal woman must amenorrheic least 12 month consider non childbearing potential . Male female patient reproductive potential must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug . Patients give write informed consent Patients suffer primary metastatic brain spinal tumor . Patients know sensitivity component IVIG formulation excipients . IgA level &lt; =60mg/dl . Treatment IVIG 6 month prior study start Patients know seropositivity HIV know diagnosis human immunodeficiency virus ( HIV ) infection . ( AIDS ) Patients significant disease , active infection uncontrolled medical condition ( e.g. , pulmonary , neurological , cardiovascular , gastrointestinal , genitourinary ) consider high risk investigational new drug treatment/ opinion investigator would exclude study Female patient pregnant breastfeeding . Patient severe and/or uncontrolled renal failure . Patient know chronic liver disease ( i.e. , chronic active hepatitis , cirrhosis ) . Patient significant history noncompliance medical regimen inability grant reliable informed consent opinion investigator , unlikely comply study protocol Patients currently participate participate another clinical trial last 30 day . Patients undergone chemotherapy last 4 week Patients treat antibiotic treatment active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>IVIg</keyword>
	<keyword>Cancer</keyword>
	<keyword>Melanoma</keyword>
</DOC>